Mechanisms of oxidative stress in diabetes: Implications for the pathogenesis of vascular disease and antioxidant therapy

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 565-574

  Pennathur, Subramaniam ^a,b   Heinecke, Jay W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Dityrosine; Inflammation; Macrovascular Disease; Microvascular Disease; Nitrotyrosine; ortho Tyrosine; Review

Indexed keywords

ANTIOXIDANT; CARBONYL DERIVATIVE; MYELOPEROXIDASE; NITRIC OXIDE; OXIDIZING AGENT;

ANTIOXIDANT ACTIVITY; DIABETES MELLITUS; GLYCOGEN METABOLISM; HUMAN; HYPERGLYCEMIA; LIPID OXIDATION; MITOCHONDRION; OXIDATION KINETICS; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; VASCULAR DISEASE; LIPID PEROXIDATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIOXIDANTS; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; LIPID PEROXIDATION; OXIDANTS; OXIDATIVE STRESS;

EID: 2542443475     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1257     Document Type: Review

References (86)

1. Skyler J: Microvascular Complications. Retinopathy and nephropathy. Endocrinol. Metab. Clin. North. Am. 30, 833-856 (2001)
2. Feldman E.L: In Diabetic Neuropathy. Philadelphia, PA: Lippincott, Williams & Wilkins. 1391-1399 pp (2001)
3. Ames B.N, M.K. Shigenaga, & T.M. Hagen: Oxidants, antioxidants and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U.S.A. 90, 7915-7922 (1993)
4. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46, 223-234 (1995)
5. Degenhardt T. P, E. Brinkmann-Frye, S. R. Thorpe, & J.W. Baynes: Role of carbonyl stress in aging and age-related diseases. In The Maillard Reaction in Foods and Medicine. J. O'Brien, H.E. Nursten, M.J.C. Crabbe, and J.M. Ames, editors. London: Royal Society of Chemistry. 3-10 (1998)
6. Semenkovich C.F, & J.W. Heinecke: The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 46, 327-334 (1997)
7. Nathan D.M: Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 352, 832-833 (1998)
8. Klein R, B.E. Klien, & S.E. Moss: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: a review. Diabetes Metab. Rev. 5, 559-570 (1989)
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 (1998)
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865 (1998)
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329, 977-986 (1993)
12. Baynes J.W. & S.R. Thorpe: Glycoxidation and lipoxidation in atherogenesis. Free Rad Biol Med 28, 1708-1716 (2000)
13. Baynes J.W. & S.R. Thorpe: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1-9 (1999)
14. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001)
15. Bucala R. & H. Vlassara: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26, 875-888 (1995)
16. Stern D.M, S.D. Yan, S.F. Yan & A.M. Schmidt: Receptor for advanced glycation end products (RAGE) and the complications of diabetes. Ageing Res Rev 1, 1-15 (2002)
17. Schmidt A.M, O. Hori, R. Cao, S.D. Yan, J. Brett, J.L. Wautier, S. Ogawa, K. Kuwabara, M. Matsumoto & D. Stern: RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45 Suppl 3, S77-80 (1996)
18. Monnier V.M: Transition metals redox: reviving an old plot for diabetic vascular disease. J. Clin. Invest. 107, 799-801 (2001)
19. Ishii H, K. Daisuke & G.L. King: Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J. Mol. Med. 76, 21-31 (1998)
20. Pfeiffer A. & H. Schatz: Diabetic microvascular complications and growth factors. Exp. Clin. Endocrinol. Diabetes. 103, 7-14 (1995)
21. Sharma K. & F.N. Ziyadeh: Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem. Nephrol. 17, 80-92 (1997)
22. Ido Y, C. Kilo & J.R. Williamson: Cytosolic NADH/NAD supply, free radicals and vascular dysfunction in early diabetes mellitus. Diabetologia 40 (Suppl. 2), 8115-8117 (1997)
23. Williamson J.R, K. Chang, M. Frangos, K.S. Hasan, Y. Ido, T. Kawamura, J.R. Nyengaard, M. van den Enden, C. Kilo & R.G. Tilton: Hyperglycemic pseudo hypoxia and diabetic complications. Diabetes 42, 801-813 (1993)
24. Nishikawa T, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.P. Hammes, I. Giardino & M. Brownlee: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790 (2000)
25. Hunt J.V, R.T. Dean & S.P. Wolf: Hydroxyl radical production and autoxidative glycosylation. Biochem. J. 256, 205-212 (1988)
26. Thornalley PJ: Monosaccharide autoxidation in health and disease. Environmental Health Perspectives 64, 297-307 (1985)
27. Huggins T.G, M.C. Wells-Knecht, N.A. Detorie, J.W. Baynes & S.R. Thorpe: Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. J Biol Chem 268, 12341-12347 (1993)
28. Huggins T.G, M.W. Staton, D.G. Dyer, N.J. Detorie, M.D. Walla, J.W. Baynes & S.R. Thorpe: o-Tyrosine and dityrosine concentrations in oxidized proteins and lens proteins with age. Ann N Y Acad Sci 663, 436-437 (1992)
29. Kaur H. & B. Halliwell: Detection of hydroxyl radicals by aromatic hydroxylation. Meth. Enzymol. 233, 67-82 (1994)
30. Miyata T, C. van Ypersele de Strihou, K. Kurokawa & J.W. Baynes: Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55, 389-399 (1999)
31. Miyata T, Y. Ueda, A. Yoshido, S. Sugiyama, Y. Iida, M. Jadoul, K. Maeda, K. Kurokawa & C. van Ypersele de Strihou: Clearance of pentosidine, an advanced glycation end-product, by different modalities of renal replacement therapy. Kidney Int. 51, 880-887 (1997)
32. Miyata T, M.X. Fu, K. Kurokawa, C. van Ypersele de Strihou, S.R. Thorpe & J.W. Baynes: Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int. 54, 1290-1295 (1998)
33. Baynes J.W: Role of oxidative stress in development of complications in diabetes. Diabetes 40, 405-412 (1991)
34. Beisswenger P.J, L.L. Moore, T. Brinck-Johnsen & T.J. Curphey: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J. Clin. Invest. 92, 2212-2217 (1993)
35. Beisswenger P.J, Z. Makita, T.J. Curphey, L.L. Moore, J. Smith, T. Brinck-Johnsen, R. Bucala & H. Vlassara: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44, 824-829 (1995)
36. Dyer D.G, J.A. Blackledge, S.R. Thorpe & J.W. Baynes: Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266, 11654-11660 (1991)
37. Dyer D.G, J.A. Dunn, S.R. Thorpe, T.J. Lyons, D.R. McCance & J.W. Baynes: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. Ann N Y Acad Sci 663, 421-422 (1992)
38. McCance D.R, D.G. Dyer, J.A. Dunn, K.E. Bailie, S.R. Thorpe, J.W. Baynes & T.J. Lyons: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91, 2470-2478 (1993)
39. Nagaraj R.H, I.N. Shipanova & F.M. Faust: Protein cross linking by the Maillard reaction: isolation, characterization, and in vivo detection of a lysine-lysine crosslink derived from methylglyoxal. J. Biol. Chem. 271, 19339-19345 (1996)
40. Sell D.R, A. Lapolla, P. Odetti, J. Fogarty & V.M. Monnier: Pentosidine formation in skin correlates with the severity of complications in individuals with long -standing IDDM. Diabetes 41, 1286-1292 (1992)
41. Leeuwenburgh C, M.M. Hardy, S.L. Hazen, P. Wagner, S. Oh-ishi, U.P. Steinbrecher & J.W. Heinecke: Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 272, 1433-1436 (1997)
42. Pennathur S, V. Jackson-Lewis, S. Przedborski & J.W. Heinecke: Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 274, 34621-34628 (1999)
43. Pennathur S, J.D. Wagner, C. Leeuwenburgh, K.N. Litwak & J.W. Heinecke: A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107, 853-860 (2001)
44. Heinecke J.W: Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 91, 12A-16A (2003)
45. Klebanoff S.J. & R.A. Clark: The Neutrophil: Function and Clinical Disorders. Amsterdam: North Holland Biochemical Press. 447-451 (1978)
46. Klebanoff S.J: Oxygen metabolism and the toxic properties of phagocytes. Ann. Intern. Med. 93, 480-489 (1980)
47. Ishii H, M.R. Jirousek, D. Koya, C. Takagi, P. Xia, A. Clermont, S.E. Bursell, T.S. Kern, L.M. Ballas, W.F. Heath, L.E. Stramm, E.P. Feener & G.L. King: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272, 728-731 (1996)
48. King G.L, H. Ishii & D. Koya: Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int Suppl 60, S77-85 (1997)
49. Du X.L, D. Edelstein, L. Rossetti, I.G. Fantus, H. Goldberg, F. Ziyadeh, J. Wu & M. Brownlee: Hyperglycemia-induced mitochondrial superoxide overproduction activates hexosamine pathway and induces plasminogen-activator inhibitor-1 expression by increasing Sp-1 glycosylation. Proc. Natl. Acad. Sci. U.S.A. 97, 12222-12226 (2000)
50. Nishikawa T, D. Edelstein & M. Brownlee: The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 77, S26-30 (2000)
51. Craven P.A, M.F. Melhem, S.L. Phillips & F.R. DeRubertis: Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50, 2114-2125 (2001)
52. Coppey L.J, J.S. Gellett, E.P. Davidson, J.A. Dunlap, D.D. Lund, D. Salvemini & M.A. Yorek: Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br. J. Pharmacol. 134, 21-29 (2001)
53. Salvemini D, Z. Wang, J.L. Zwier, A. Samouilov, H. Macarthur, T. Misko, M.G. Currie, S. Cuzzocrea, J.A. Sikorski & D.P. Riley: A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 286, 304-306 (1999)
54. Hammes H.P, X. Du, D. Edelstein, T. Taguchi, T. Matsumura, Q. Ju, J. Lin, A. Bierhaus, P. Nawroth, D. Hannak, M. Neumaier, R. Bergfeld, I. Giardino & M. Brownlee: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9, 294-299 (2003)
55. Bucala R, Z. Makita, T. Koschinsky, A. Cerami & H. Vlassara: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 90, 6434-6438 (1993)
56. Bucala R, Z. Makita, G. Vega, S. Grundy, T. Koschinsky, A. Cerami & H. Vlassara: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91, 9441-9445 (1994)
57. Hunt J.V, C.C. Smith & S.P. Wolf: Oxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39, 1420-1424 (1990)
58. Kawamura M, J.W. Heinecke & A. Chait: Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94, 771-778 (1994)
59. Fu M.X, J.R. Requena, A.J. Jenkins, T.J. Lyons, J.W. Baynes & S.R. Thorpe: The advanced glycation end product, N-epsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271, 9982-9986 (1996)
60. Requena J.R, M.U. Ahmed, C.W. Fountain, T.P. Degenhardt, S. Reddy, C. Perez, T.J. Lyons, A.J. Jenkins, J.W. Baynes & S.R. Thorpe: Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo. J Biol Chem 272, 17473-17479 (1997)
61. Requena J.R, M.X. Fu, M.U. Ahmed, A.J. Jenkins, T.J. Lyons, J.W. Baynes & S.R. Thorpe: Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 322 (Pt 1), 317-325 (1997)
62. Requena J.R, M.-X. Fu, M.U. Ahmed, A.J. Jenkins, T.J. Lyons & S.R. Thorpe: Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol. Dial. Transplant. 11 (Suppl 1), 48-53 (1996)
63. Mezzetti A, F. Cipollone & F. Cuccurullo: Oxidative stress and cardiovascular complications of diabetes: isoprostanes as new markers on an old paradigm. Cardiovas. Res. 47, 475-488 (2000)
64. Davi G, G. Ciabattoni, A. Consoli, A. Mezzetti, A. Falco, S. Santarone, E. Pennese, E. Vitacolonna, T. Bucciarelli, F. Constantini, S. Capani & C. Patarano: In vivo formation of 8-iso-prostaglandin F2 alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99, 224-229 (1999)
65. Onorato J.M, A.J. Jenkins, S.R. Thorpe & J.W. Baynes: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 275, 21177-21184 (2000)
66. Voziyan P.A, T.O. Metz, J.W. Baynes & B.C. Hudson: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277, 3397-3403 (2002)
67. Brownlee M, H. Vlassara, A. Kooney, P. Ulrich & A. Cerami: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232, 1629-1632 (1986)
68. Edelstein D. & M. Brownlee: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35, 96-97 (1992)
69. Hammes H.P, S. Martin, K. Federlin, K. Geisen & M. Brownlee: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88, 11555-11558. (1991)
70. Hammes H.P, M. Brownlee, D. Edelstein, M. Saleck, S. Martin & K. Federlin: Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37, 32-35 (1994)
71. Ihm S, J. Hyung, S. Park & J. Ihm: Effect of aminoguanidine on lipid-peroxidation in streptozotocin-induced diabetic rats. Metabolism 48, 1141-1145 (1999)
72. Stitt A, T.A. Gardiner, N.L. Alderson, P. Canning, N. Frizzell, N. Duffy, C. Boyle, A.S. Januszewski, M. Chachich, J.W. Baynes, S.R. Thorpe & N.L. Anderson: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51, 2826-2832 (2002)
73. Degenhardt T.P, N.L. Alderson, D.D. Arrington, R.J. Beattie, J.M. Basgen, M.W. Steffes, S.R. Thorpe & J.W. Baynes: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61, 939-950 (2002)
74. Wells-Knecht M.C, T.J. Lyons, D.R. McCance, S.R. Thorpe & J.W. Baynes: Age-dependent increase in orthotyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 100, 839-846 (1997)
75. Dyer D.G, J.A. Dunn, S.R. Thorpe, K.E. Bailie, T.J. Lyons, D.R. McCance & J.W. Baynes: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91, 2463-2469 (1993)
76. Litwak K.N, W.T. Cefalu & J.D. Wagner: Chronic hyperglycemia increases arterial low-density lipoprotein metabolism and atherosclerosis in cynomolgus monkeys. Metabolism 47, 947-954 (1998)
77. Litwak K.N, W.T. Cefalu & J.D. Wagner: Streptozotocin-Induced Diabetes Mellitus in Cynomolgus Monkeys: Changes in Carbohydrate Metabolism, Skin Glycation, and Pancreatic Islets. Laboratory Animal Science 48, 172-178 (1998)
78. Lamb D, M.J. Mitchinson & D.S. Leake: Transition metals within human athersclerotic lesions can catalyze the oxidation of low density lipoprotein by macrophages. FEBS Lett. 374, 12-16 (1995)
79. Swain J. & J.M.C. Gutteridge: Prooxidant iron and copper, with ferroxidase and xanthine oxidase activity in human atherosclerotic material. FEBS Lett. 368, 515-515 (1995)
80. Yim H, S. Kang, Y. Hah, P. Boon Chock & M.B. Yim: Free radicals generated during the glycation reaction of amino acids by methylglyoxal. J. Biol. Chem. 270, 28228-28233 (1995)
81. Saxena A.K, P. Saxena, X. Wu, M. Obrenovich, M.F. Weiss & V.M. Monnier: Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem. Biophys. Res. Commun. 260, 332-338 (1999)
82. Lee C, M.B. Yim, P. Boon Chock, H. Yim & S. Kang: Oxidation-reduction Properties of Methylglyoxal-modified protein in relation to free radical generation. J. Biol. Chem. 273, 25272-25278 (1998)
83. Yusuf S, G. Dagenais, J. Pogue, J. Bosch & P. Sleight: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342, 154-160 (2000)
84. Ziegler D, M. Hanefeld, K.J. Ruhnau, H. Hasche, M. Lobisch, K. Schutte, G. Kerum & R. Malessa: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22, 1296-1301 (1999)
85. Reljanovic M, G. Reichel, K. Rett, M. Lobisch, K. Schuette, W. Moller, H.J. Tritschler & H. Mehnert: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 31, 171-179 (1999)
86. Boaz M, S. Smetana, T. Weinstein, Z. Matas, U. Gafter, A. Iaina, A. Knecht, Y. Weissgarten, D. Brunner, M. Fainaru & M.S. Green: Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE):randomised placebo controlled trial. Lancet 356, 1213-1218 (2000)